Questions: Antimicrobial Resistance Control Strategies

Question 1

A physician prescribes broad-spectrum antibiotics for a patient with an obvious viral upper respiratory infection, reasoning: 'It's just one patient — my prescribing decision won't measurably affect resistance rates.' What is structurally wrong with this reasoning?

• A. Nothing — individual prescribing decisions are too small to contribute to population-level resistance
• B. The antibiotic will harm this patient directly by eliminating beneficial gut microbiota
• C. Each unnecessary prescription adds selective pressure to the shared pathogen pool, creating an externality that affects others — the collective action problem means this reasoning is self-undermining when applied universally
• D. Viral infections sometimes have bacterial co-infections, so the prescription may be medically justified

Answer: (C)

This is the collective action problem at the heart of AMR epidemiology. Every individual prescriber can reason 'my single decision is negligible' — but when every prescriber reasons this way, the aggregate effect is enormous selective pressure on pathogen populations. The physician's antibiotics affect resistant organism selection in that patient's environment, their hospital, and eventually the broader pathogen pool. AMR is a tragedy-of-the-commons problem precisely because no individual actor internalizes the full cost of their prescribing decision.

Question 2

A hospital implements rigorous contact precautions for MRSA-positive patients while simultaneously running an antimicrobial stewardship program to reduce broad-spectrum antibiotic use. How do these interventions interact?

• A. They are redundant — if IPC prevents MRSA transmission, stewardship is unnecessary
• B. Stewardship slows the emergence of resistance by reducing selective pressure; IPC slows its spread once it has emerged — the two address different phases of the same problem and are complementary
• C. IPC reduces infections, which reduces antibiotic use, making stewardship programs superfluous
• D. Both interventions target transmission, so they achieve the same goal through different mechanisms

Answer: (B)

Stewardship (demand-side) and IPC (transmission-side) are complementary because they target different steps in the resistance problem. Stewardship reduces the selective pressure that favors resistant mutants — slowing emergence. IPC interrupts transmission chains so that resistance, once it emerges, doesn't spread through patient populations. Neither alone is sufficient: stewardship without IPC allows resistant organisms to spread; IPC without stewardship does nothing to slow the rate at which resistance develops.

Question 3

Once antibiotic use is substantially reduced in a healthcare facility, resistant bacterial strains will typically be outcompeted by sensitive strains and disappear within months.

• T. True
• F. False

Answer: False

This is a common and dangerous misconception. Resistance is an evolutionary change that does not reliably reverse when selective pressure is removed. Resistant strains can persist in hospital environments, patient microbiomes, and broader ecological reservoirs for years. Mobile resistance genes spread between organisms through horizontal gene transfer, independent of antibiotic pressure. The correct model is that resistance can be slowed and managed — not that it self-resolves — which is why prevention is far more cost-effective than attempting to reverse established resistance.

Question 4

Agricultural antibiotic use poses a distinct antimicrobial resistance challenge because resistance genes can transfer between animal and human pathogens via mobile genetic elements.

• T. True
• F. False

Answer: True

Mobile genetic elements — plasmids, transposons, integrons — can carry resistance genes across species barriers, making agricultural antibiotic use a direct contributor to resistance in human pathogens. Growth-promotion doses of antibiotics in livestock create enormous selective pressure on animal gut microbiomes, selecting for resistant organisms whose resistance determinants can subsequently transfer. This means hospital stewardship alone is insufficient — AMR control requires addressing agricultural, environmental, and global dimensions.

Question 5

Why is antimicrobial resistance described as a 'collective action problem,' and what does this mean for how it must be addressed?

Model answer: AMR is a collective action problem because individual antibiotic use decisions impose costs on others — selecting for resistant organisms in shared environments — while the benefits of restraint (preserving antibiotic effectiveness) are diffuse and shared. No individual prescriber, hospital, or country internalizes the full cost of overuse, creating incentives to underinvest in stewardship. Solutions require coordinated policies across institutions, sectors (human, agricultural, veterinary), and nations to align individual incentives with collective benefit.

The tragedy-of-the-commons structure means the rational individual choice (prescribe when in doubt, use broad-spectrum) is collectively self-defeating. Stewardship programs change the incentive structure: making prescribing data visible, requiring justification for restricted antibiotics, and creating accountability that individuals acting alone would not face. The global dimension matters equally: any country's stewardship gains can be undermined by resistance developing and spreading elsewhere, which is why international surveillance frameworks like WHO's GLASS system exist.